These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7435345)

  • 1. Bilateral orchiectomy in patients with progressive advanced prostatic cancer.
    Denis L; Nowe P
    Acta Urol Belg; 1980 Jan; 48(1):113-6. PubMed ID: 7435345
    [No Abstract]   [Full Text] [Related]  

  • 2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Prout GR
    Surg Forum; 1970; 21():540-1. PubMed ID: 5535268
    [No Abstract]   [Full Text] [Related]  

  • 4. [Subcapsular orchiectomy using the ultrasonic surgical aspirator in patients with advanced prostatic cancer].
    Yasumoto R; Minami H; Yoshihara H; Maekawa T; Ameno Y; Hayashi S; Nishisaka N; Kishimoto T
    Hinyokika Kiyo; 1992 Dec; 38(12):1379-81. PubMed ID: 1288226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Koontz WW; Prout GR
    Invest Urol; 1972 Mar; 9(5):423-5. PubMed ID: 5016026
    [No Abstract]   [Full Text] [Related]  

  • 6. [Primary orchiectomy in prostatic cancer].
    Johansen S; Sander S
    Tidsskr Nor Laegeforen; 1982 Sep; 102(25):1267-9. PubMed ID: 6187086
    [No Abstract]   [Full Text] [Related]  

  • 7. Hormonal effect of subcapsular orchiectomy versus total orchiectomy.
    Tacker JR; Coker JE; Hosty TA; Albers DD
    Invest Urol; 1980 May; 17(6):441-2. PubMed ID: 7372430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW; Dunn SR; Ferguson DW; Lomas G; Niazi Z; Stratte PT
    J Urol; 2000 Jan; 163(1):181-6. PubMed ID: 10604342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Castration as a better alternative to estrogen in the treatment of prostatic cancer].
    Edhag O; Henriksson P; Linde B; Eriksson A; Collste L
    Lakartidningen; 1987 Oct; 84(42):3394-6. PubMed ID: 3683028
    [No Abstract]   [Full Text] [Related]  

  • 13. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
    Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
    Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
    Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
    Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On gestagen treatment of advanced prostatic carcinoma.
    Sander S; Nissen-Meyer R; Aakvaag A
    Scand J Urol Nephrol; 1978; 12(2):119-21. PubMed ID: 694436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma.
    Iversen P; Rasmussen F; Christensen IJ
    Scand J Urol Nephrol Suppl; 1994; 157():41-7. PubMed ID: 7939452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral orchiectomy in the management of stage D-2 prostate cancer.
    Guinan P; Firfer R; Targonski P; Rubenstein M
    Int Surg; 1993; 78(1):73-5. PubMed ID: 8473090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adrenal cortex and prostatic cancer.
    Peeling WB; Griffiths K
    Proc R Soc Med; 1974 Nov; 67(11):1156-8. PubMed ID: 4438298
    [No Abstract]   [Full Text] [Related]  

  • 20. Subcapsular versus total orchiectomy in the treatment of advanced prostate cancer: a randomized trial.
    Roosen JU; Klarskov OP; Mogensen P
    Scand J Urol Nephrol; 2005; 39(6):464-7. PubMed ID: 16303721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.